Feb 10 2022 GlaxoSmithKline plc LSE/NYSE GSK today announced that China’s National Medical Products Administration NMPA has approved Benlysta belimumab for the treatment of adult patients with active lupus nephritis LN who are receiving standard of care. The approval extends the current indication in China as add on therapy in adults and
Dec 03 2019 On November 22 2019 the American National Standards Institute ANSI hosted a bilateral meeting with a delegation from China s National Medical Products Administration NMPA . Under the newly formed State Administration for Market Regulation SAMR NMPA is the Chinese regulatory body for Chinese drugs and medical devices and has the responsibility
Jun 01 2021 National Medical Products Administration NMPA Number of doses 1 and 2 Diluent Not applicable Route of administration Intramuscular
Dec 16 2021 China s National Medical Products Administration Approves NUZYRA omadacycline for the Treatment of Bacterial Pneumonia and Skin Infections Paratek earns 6 million milestone payment from Zai Labread this article along with other careers information tips and advice on BioSpace
Dec 16 2021 China s National Medical Products Administration Approves NUZYRA omadacycline for the Treatment of Bacterial Pneumonia and Skin Infections Paratek earns 6 million milestone payment from Zai Lab
Jun 20 2019 Background. On May 8 2018 the China National Medical Products Administration NMPA approved anlotinib an orally administered anti angiogenesis inhibitor for the treatment of patients with advanced non small cell lung cancer NSCLC who have progressed after treatment with two or more lines of prior systemic chemotherapy.
Aug 09 2019 China National Medical Products Administration Approves Biktarvy Bictegravir Emtricitabine and Tenofovir Alafenamide for Treatment of HIV 1 Infection Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks
China National Medical Products Administration approves MR guided Focused UltrasoundInsightec. HAIFA Israel and MIAMI Florida February 10 2021 Insightec a global healthcare company focused on creating the next generation of patient care announced it received market approval by The National Medical Products Administration NMPA
Announcement of National Medical Products Administration and National Intellectual Property Administration on the Issuance of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes Interim Regulatory Information.
Jun 20 2019 Europe PMC is an archive of life sciences journal literature. Background On May 8 2018 the China National Medical Products Administration NMPA approved anlotinib an orally administered anti angiogenesis inhibitor for the treatment of patients with advanced non small cell lung cancer NSCLC who have progressed after treatment with two or more lines of
Nov 12 2020 BRIEF China s National Medical Products Administration Accepts F BRIEF China s National Medical Products Administration Accepts Fosun Pharma Unit s Clinical Trial Application For mRNA Vaccine BNT162b2
Aug 11 2020 China National Medical Products Administration Approves Truvada for HIV Pre Exposure Prophylaxis PrEP Truvada is the First HIV PrEP Medicine Approved in China FOSTER CITY Calif. BUSINESS WIRE Gilead Sciences Inc. Nasdaq GILD today announced that the China National Medical Products Administration NMPA has approved
The National Medical Products Administration NMPA a vice ministerial level body under the State Administration for Market Regulation SAMR is responsible for creating and supervising the implementation of policies plans and standards governing the quality and safety of drugs cosmetics and medical devices.
Jun 09 2020 NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES LIPIODOL ULTRA FLUID FOR TRANS ARTERIAL CHEMOEMBOLIZATION OF INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA HCC IN
Dec 04 2018 FOSTER CITY Calif. BUSINESS WIRE Dec. 4 2018 Gilead Sciences Inc. NASDAQ GILD announced today that the National Medical Products Administration NMPA has approved Harvoni ledipasvir 90 mg/sofosbuvir 400 mg in China for the treatment of chronic hepatitis C virus HCV genotype 1 6 infection in adults and adolescents aged 12 to
Dec 04 2021 SHANGHAI Dec. 4 2021 /PRNewswire/ Shanghai Henlius Biotech Inc. 2696.HK announced that bevacizumab biosimilar Hanbeitai developed and manufactured by Henlius independently has been approved by the National Medical Products Administration NMPA . It is indicated for the treatment of metastatic colorectal cancer mCRC and
Mar 25 2020 On 18.03.2020 the NMPA National Medical Products Administration issued the 2019 Annual Report for Medical Device Registration. In 2019 the NMPA received a total of 9 104 applications for the initial registration registration renewals and changes in licensing items of Class III Domestic and Overseas and Class II Overseas medical devices an increase of
Over 945m doses of COVID 19 vaccines administered in China. More than 945.1 million doses of COVID 19 vaccines have been administered in China as of Wednesday the National Health Commission said on June 17.
Efficacy of Aumolertinib HS 10296 in Patients With Advanced EGFR T790M NSCLC Updated Post National Medical Products Administration Approval Results From the APOLLO Registrational Trial J Thorac Oncol. 2021 Nov 19S1556 0864 21 03323 2. doi 10.1016/j.jtho.2021.10.024.
Jan 14 2021 The China National Medical Products Administration NMPA has granted tislelizumab full approval for first line treatment of patients with advanced squamous non small cell lung cancer NSCLC in
Apr 10 2020 Tislelizumab is approved by the China National Medical Products Administration NMPA as a treatment for patients with classical Hodgkin’s lymphoma who received at least two prior therapies and
Feb 14 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first line treatment of people with extensive stage small cell lung cancer
National Medical Products Administration. Dec 07. CB Scientific Inc. Executed Manufacturing Letter of Intent with Shenzhen Pump Medical System Co. Ltd. Partnership to provide high volume manufacturing capability and facilitate obtaining requisite government approvals. News 0
Nov 29 2019 SHENZHEN China Nov. 29 2019 /PRNewswire/ National Medical Products Administration NMPA Approves Chipscreen Bioscience s Chidamide Epidaza for Breast Cancer Indication
Mar 31 2020 Announcement NO.5 of 2020 General Administration of Customs and National Medical Products Administration on Ensuring the Orderly Export of Medical Supplies . The COVID 19 pandemic is sprawling across the world at a faster pace. On top of our domestic efforts in fighting the epidemic it is important that we export medical products in an
Dec 16 2021 Paratek earns 6 million milestone payment from Zai Lab. BOSTON Dec. 16 2021 GLOBE NEWSWIRE Paratek Pharmaceuticals Inc. Nasdaq PRTK today announced that the company’s partner in China Zai Lab Limited NASDAQ ZLAB HKEX 9688 received approval from the National Medical Products Administration NMPA of China of NUZYRA
Dec 31 2020 Tag China s National Medical Products Administration. Posted in China China’s first vaccine hustled to market as race to inoculate 1.3bn speeds up. by AFP 08 43 31 December 2020 17 46 31
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
No.18,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
